一分钟看懂
这是一项关于乳腺癌的III 期研究，登记的药物或干预包括Tucatinib；Trastuzumab；Pertuzumab；Combination product: Trastuzumab + Pertuzumab；Placebo，当前状态为研究进行中，已停止招募。登记地点显示中国合肥、广州、梅州、柳州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tucatinib；Trastuzumab；Pertuzumab；Combination product: Trastuzumab + Pertuzumab；Placebo · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Second Hospital of Anhui Medical University · 合肥
- Guangdong Provincial People's Hospital · 广州
- Meizhou People's Hospital · 梅州
- Liuzhou People's Hospital · 柳州
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- The People's Hospital of Guangxi Zhuang Autonomous Region · 南宁
- The first Affiliated Hospital of Hainan Medical University · 海口
- Affiliated Hospital of Hebei University · 保定
- Henan Cancer Hospital · 郑州
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology · 武汉
- Hubei Cancer Hospital · 武汉
- The Second Xiangya Hospital of Central South University · 长沙
- Nanjing Medical University (NMU) - Jiangsu Province Hospital · 南京
- The Second Affiliated Hospital of Nanchang University · 南昌
- The First Hospital of Jilin University · 长春
- Liaoning Cancer Hospital & Insitute · 沈阳
- The First Affiliated Hospital of China Medical University · 沈阳
- Ruijin Hospital of Shanghai Jiaotong University School of Medicine · 上海
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Shaanxi Provincial People's Hospital · 西安
- Jinan Central Hospital · 济南
- Linyi Cancer Hospital · 临沂
- Zhejiang Cancer Hospital · 杭州
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · 杭州
- The Second Affiliated Hospital of Zhejiang University School of Medicine · 杭州
- Beijing Hospital · 北京
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Cancer Hospital Binhai Campus · 天津
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Centrally confirmed HER2+ breast carcinoma according to the 2018 American Society of Clinical Oncologists (ASCO) College of American Pathologists (CAP) guidelines prior to randomization (defined as a 3+ score on immunohistochemistry (IHC) and/or 2+ IHC and concurrent positive by ISH).
- * Have unresectable locally advanced or metastatic disease.
- If recurrent (after \[neo\]adjuvant therapy), must be at least 6 month treatment free from any trastuzumab and pertuzumab received in the early breast cancer setting for advanced HER2+ disease.
- * Have received 4-8 cycles of pre-study induction therapy including only trastuzumab, pertuzumab, and taxane as first-line of therapy for the treatment of advanced breast cancer prior to study enrollment. Participants are eligible provided they are without evidence of disease progression following completion of induction therapy.
- * Known hormone receptor status (per local guidelines; may be hormone receptor positive \[HR+\] or negative \[HR-\])
- * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- * CNS Inclusion
- Based on screening contrast-enhanced brain magnetic resonance imaging (MRI), participants may have any of the following:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05132582；登记信息更新于 2026-09-29；本站同步于 2026-10-08。